Skip to main content

Nasopharyngeal Carcinoma

  • Chapter
  • First Online:
Pediatric Head and Neck Tumors

Abstract

Nasopharyngeal carcinoma (NPC) is a very rare malignancy in children; only 1 % of all cases of NPC occur in patients younger than 19 years of age. Childhood NPC is commonly associated with Epstein–Barr virus, and the biology, pathology, and clinical presentation are very similar to the endemic form of NPC. Clinically, childhood NPC presents with advanced locoregional disease, with large primary tumors and bilateral cervical nodal metastases. The differential diagnosis includes infectious diseases, juvenile angiofibroma, and nasopharyngeal malignancies, such as NUT (nuclear protein in testis) midline carcinoma, rhabdomyosarcoma, and other soft tissue sarcomas, sinonasal carcinoma, and lymphomas. Childhood NPC is very responsive to chemotherapy and radiation therapy and recommended treatment usually includes a cisplatin-based induction phase followed by chemoradiation. With this approach, more than 80 % of children with NPC are cured. However, long-term effects are usually common and may be severe. The most frequent late effects include xerostomia, dental decay, trismus, swallowing dysfunction, hearing loss, and endocrine deficits such as hypothyroidism and hypopituitarism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Sultan I, Casanova M, Ferrari A, Rihani R, Rodriguez-Galindo C. Differential features of nasopharyngeal carcinoma in children and adults: a SEER study. Pediatr Blood Cancer. 2010;55:279–84.

    Article  PubMed  Google Scholar 

  2. Fandi A, Cvitkovic E. Biology and treatment of nasopharyngeal cancer. Curr Opin Oncol. 1995;7:255–63.

    Article  PubMed  CAS  Google Scholar 

  3. Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet. 1997;350:1087–91.

    Article  PubMed  CAS  Google Scholar 

  4. Zeng Y, Zhang LG, Wu YC, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer. 1986;36:545–8.

    Article  Google Scholar 

  5. de-Vathaire F, Sancho-Garnier H, de-The H, et al. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study. Int J Cancer. 1988;42:176–81.

    Article  PubMed  CAS  Google Scholar 

  6. Pathmanathan R, Prasad U, Chandrika G, et al. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx: variants of Epstein-Barr virus-infected neoplasia. Am J Pathol. 1995;146:1355–67.

    PubMed  CAS  Google Scholar 

  7. Lo YMD, Chan ATC, Chan LYS, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000;60:6878–81.

    PubMed  CAS  Google Scholar 

  8. Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol. 1994;21:376–81.

    PubMed  CAS  Google Scholar 

  9. Sam CK, Brooks LA, Niedobitek G, et al. Analysis of Epstein-Barr virus infection in naospharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. Int J Cancer; 1993;53:957–62.

    Article  PubMed  CAS  Google Scholar 

  10. Wu TC, Mann RB, Epdtein JI, et al. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma: a morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embeded carcinoma specimens. Am J Pathol. 1991;138:1461–9.

    PubMed  CAS  Google Scholar 

  11. Murray PG, Niedobitek G, Kremmer E, et al. In situ detection of the Epstein-Barr virus-encoded nuclear antigen 1 in oral hairy leukoplakia and virus-associated carcinomas. J Pathol; 1996;178:44–7.

    Article  PubMed  CAS  Google Scholar 

  12. Hording U, Nielsen HW, Albeck H, et al. Nasopharyngeal carcinoma—histopathological types and association with Epstein-Barr virus. Eur J Cancer B Oral Oncol. 1993;29B:137–9.

    Article  PubMed  CAS  Google Scholar 

  13. Cheuk DKL, Billups CA, Martin MG, et al. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer. 2011;117:197–206.

    Article  PubMed  CAS  Google Scholar 

  14. Casanova M, Bisogno G, Gandola L, et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents. Cancer. 2012;118:2718–25.

    Article  PubMed  Google Scholar 

  15. Buehrlen M, Zwaan CM, Granzen B, et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results.from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer. 2012;118:4892–900.

    Article  PubMed  CAS  Google Scholar 

  16. French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol. 2012;7:247–65.

    Article  PubMed  CAS  Google Scholar 

  17. Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012;18:5773–9.

    Article  PubMed  Google Scholar 

  18. Schwartz BE, Hofer MD, Lemieux ME, et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011;71:2686–96.

    Article  PubMed  CAS  Google Scholar 

  19. Cheuk DK, Sabin ND, Hossain M, et al. PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:1097–106.

    Article  PubMed  Google Scholar 

  20. Pharynx. In: Edge SB, Byrd DR, Compton CC et al., Editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. pp. 41–56.

    Google Scholar 

  21. Sanguineti G, Geara FB, Garden AS, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys. 1997;37:985–96.

    Article  PubMed  CAS  Google Scholar 

  22. Orbach D, Brisse H, Helfre S, et al. Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: radiotherapy dose adaptation after chemotherapy response to minimize late effects. Pediatr Blood Cancer. 2008;50:849–53.

    Article  PubMed  Google Scholar 

  23. Perez CA, Devineni VR, Marcial-vega V, Marks JE, Simpson JR, Kucik N. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys. 1992;23:271–80.

    Article  PubMed  CAS  Google Scholar 

  24. Langendijk JA, Leemans C, Buter J, Berkhof J. Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004;22:4604–12.

    Article  PubMed  CAS  Google Scholar 

  25. Dewit L. Combined treatment of radium and cis-diamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys. 1987;13:403–26.

    Article  PubMed  CAS  Google Scholar 

  26. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13:163–71.

    Article  PubMed  Google Scholar 

  27. Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol;2002:1845–52.

    Google Scholar 

  28. Johnson FM, Garden A, Palmer JL, et al. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer. 2004;100:991–8.

    Article  PubMed  CAS  Google Scholar 

  29. Zhang L, Zhang Y, Huang PY, Xu F, Peng PJ, Guan ZZ. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol. 2008;61:33–8.

    Article  PubMed  CAS  Google Scholar 

  30. Louis CU, Straathof K, Bollard CM, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010;33:983–90.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carlos Rodriguez-Galindo MD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rodriguez-Galindo, C. (2014). Nasopharyngeal Carcinoma. In: Rahbar, R., Rodriguez-Galindo, C., Meara, J., Smith, E., Perez-Atayde, A. (eds) Pediatric Head and Neck Tumors. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8755-5_30

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8755-5_30

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8754-8

  • Online ISBN: 978-1-4614-8755-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics